Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy

Cellular Oncology, Journal Year: 2022, Volume and Issue: 45(3), P. 333 - 353

Published: May 19, 2022

Language: Английский

---

(Im)maturity in Tumor Ecosystem

Frontiers in Oncology, Journal Year: 2022, Volume and Issue: 11

Published: Jan. 25, 2022

Tumors have special features that make them distinct from their normal counterparts. Immature cells in a tumor mass and critical contributions to the tumorigenesis will open new windows toward cancer therapy. Incomplete cellular development brings versatile unique functionality ecosystem, such as what is seen for highly potential embryonic cells. There evidence maturation of certain types this ecosystem can recover sensitivity tumor. Therefore, understanding more about mechanisms contributed immaturity render therapeutic approaches Targeting be exploited supplementary current immunotherapeutic treatment schedules, immune checkpoint inhibitor (ICI) The key focus review discuss impact (im)maturity ecosystems on progression, focusing mainly cell compartment tumor, well stemness

Language: Английский

---

HHLA2 immune-regulatory roles in cancer

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 162, P. 114639 - 114639

Published: April 1, 2023

Human endogenous retrovirus H long terminal repeat-associating protein 2 (HHLA2 or B7-H7) is a newly discovered B7 family member. HHLA2 aberrantly expressed in solid tumors and exerts co-stimulatory co-inhibitory activities dependent on interaction with counter receptors. represents effects upon transmembrane immunoglobulin domain containing (TMIGD2, also called CD28H), but its killer cell Ig-like receptor, three Ig domains cytoplasmic tail 3 (KIR3DL3) renders effects. TMIGD2 mainly resting naïve T cells, whereas expression of KIR3DL3 occurs activated cells. HHLA2/KIR3DL3 attenuates responses from both innate adaptive anti-tumor immunity, the activity within this axis regarded as biomarker weak prognosis cancer patients. promotes CD8+ exhaustion induces macrophage polarity toward pro-tumor M2 phenotype. diverse profile tumor stroma. Tumoral presumably higher compared programmed death-ligand 1 (PD-L1), co-expression PD-L1 indicative more severe outcomes. A suggested strategy patients HHLA2high to use monoclonal antibodies for specifically suppressing inhibitory receptor KIR3DL3, not ligand. can be target development agonistic bispecific hampering resistance death-1 (PD-1)/PD-L1 blockade therapy.

Language: Английский

---

The impact of hypoxia on extracellular vesicle secretome profile of cancer

Medical Oncology, Journal Year: 2023, Volume and Issue: 40(5)

Published: March 24, 2023

Language: Английский

---

Extracellular vesicles-powered immunotherapy: Unleashing the potential for safer and more effective cancer treatment

Archives of Biochemistry and Biophysics, Journal Year: 2024, Volume and Issue: 756, P. 110022 - 110022

Published: April 30, 2024

Language: Английский

---